Passage Bio Reports Q1 2025 Financial Results

Passage Bio, Inc. ( (PASG) ) has released its Q1 earnings. Here is a breakdown of the information Passage Bio, Inc. presented to its investors.

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing therapies for neurodegenerative diseases, with its lead product candidate targeting frontotemporal dementia. In its latest earnings report for the quarter ended March 31, 2025, Passage Bio reported a net loss of $15.4 million, a slight improvement from the $16.7 million loss in the same period last year. The company has been actively managing its resources, evidenced by a reduction in workforce and the cessation of lab operations in Hopewell, New Jersey, which led to a $2.6 million impairment charge. Despite these challenges, Passage Bio maintains a strong cash position with $63.4 million in cash and cash equivalents, up from $37.6 million at the end of 2024, primarily due to strategic financial management and asset sales. The company’s management remains focused on advancing its clinical programs and exploring additional funding options to support its operations and product development efforts. Looking ahead, Passage Bio is committed to navigating the complexities of the biotechnology sector and aims to achieve significant milestones in the development of its genetic therapies.